References
- Rosinol L, Cibeira M T, Blade J, Esteve J, Aymerich M, Rozman M, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004; 89: 832–836
- Avigdor A, Raanani P, Levi I, Hardan I, Ben-Bassat I. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide in multiple myeloma. Leuk Lymphoma 2001; 42: 683–687
- Damaj G, Mohty M, Vey N, Dincan E, Bouabdallah R, Faucher C, et al. Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. Eur J Haematol 2004; 73: 402–406
- Hernandez J M, Garcia-Sanz R, Golvano E, Blade J, Fernandez-Calvo J, Trujillo J, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Hematol 2004; 127: 159–164
- Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades S, Hayashi T, et al. NF-kappaB as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639–16647
- Wasser K, Moehler T, Neben K, Nosas S, Heiss J, Goldschmidt H, et al. Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED Chemotherapy. Rofo 2004; 176: 1285–1295